Mild psoriasis as a suitable model for proof-of-mechanism in a phase 1B setting: Results from a double-blind placebo-controlled trial with guselkumab.

Early clinical development of novel psoriasis therapies is hampered by a decreasing number of moderate-to-severe psoriasis patients eligible for participation in trials since efficacious treatments, such as biologics, have become widely available. The aim of this study was to establish mild psoriasis patients as a suitable alternative trial population since these patients are generally not eligible for these treatments.